{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:50:00Z","timestamp":1789498200382,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C2095456"],"award-info":[{"award-number":["2021R1A2C2095456"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114206","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:50:55Z","timestamp":1720097455000},"page":"114206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer"],"prefix":"10.1016","volume":"208","author":[{"given":"Siyeon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongyeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonoh","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kijong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boram","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114206_bib1","series-title":"Board WCoTE, editor. Thoracic Tumours","first-page":"64","article-title":"Invasive non-mucinous adenocarcinoma of the lung","author":"Cooper","year":"2021"},{"key":"10.1016\/j.ejca.2024.114206_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.114206_bib3","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib4","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114206_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase 1\/2 trial","author":"Riely","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114206_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114206_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.114206_bib10","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.annonc.2022.02.044","article-title":"35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.114206_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"Turner","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.114206_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.10.041","article-title":"Translesion polymerases drive microhomology-mediated break-induced replication leading to complex chromosomal rearrangements","volume":"60","author":"Sakofsky","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejca.2024.114206_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s13258-020-00949-1","article-title":"A newly developed capture-based sequencing panel for genomic assay of lung cancer","volume":"42","author":"Im","year":"2020","journal-title":"Genes Genom"},{"key":"10.1016\/j.ejca.2024.114206_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41588-021-01000-z","article-title":"The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy","volume":"54","author":"van Leen","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2024.114206_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41588-021-00951-7","article-title":"Chromothripsis followed by circular recombination drives oncogene amplification in human cancer","volume":"53","author":"Rosswog","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2024.114206_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114206_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114206_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.114206_bib20","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114206_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.1889","article-title":"MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis","volume":"15","author":"Stein","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114206_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-018-9771-8","article-title":"MACC1-the first decade of a key metastasis molecule from gene discovery to clinical translation","volume":"37","author":"Radhakrishnan","year":"2018","journal-title":"Cancer Metastas-- Rev"},{"key":"10.1016\/j.ejca.2024.114206_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2024.114206_bib24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/2159-8290.CD-15-0654","article-title":"EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib","volume":"5","author":"Gallant","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114206_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lungcan.2017.04.004","article-title":"Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC","volume":"108","author":"Knebel","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.114206_bib26","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/0008-5472.CAN-16-2359","article-title":"Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors","volume":"77","author":"Nukaga","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.114206_bib27","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/onc.2009.526","article-title":"Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor","volume":"29","author":"Ercan","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2024.114206_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.114206_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2024.114206_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejca.2024.114206_bib31","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1172\/JCI28656","article-title":"Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer","volume":"116","author":"Engelman","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ejca.2024.114206_bib32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114206_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtho.2023.08.029","article-title":"Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion","volume":"19","author":"Hamada","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib34","article-title":"The impact of on-target resistance mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 insertion mutation active tyrosine kinase inhibitors","volume":"5","author":"Kobayashi","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2024.114206_bib35","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00432-020-03239-1","article-title":"Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes","volume":"146","author":"Mu","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114206_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073992","article-title":"Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON): an international real-world safety and efficacy analysis","volume":"25","author":"Illini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2024.114206_bib37","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-B153","article-title":"Abstract B153: resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations","volume":"22","author":"Le","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2024.114206_bib38","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1158\/1538-7445.AM2022-2781","article-title":"Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib","volume":"82","author":"Vincent","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.114206_bib39","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1200\/JCO.2011.35.3979","article-title":"Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations","volume":"29","author":"Yuan","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:20Z","timestamp":1762342520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"alternative-id":["S0959804924008621"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114206","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114206"}}